Therapy Areas: Devices
VoxNeuro Teams with Boston University on Clinical Studies Focusing on Concussion, Alzheimer's Disease
8 September 2022 - - US-based commercial stage Software-as-a-Medical-Device brain health company VoxNeuro Inc has formed a new partnership with Boston University, the company said.

In partnership with BU, VoxNeuro has launched two studies that will evaluate its cognitive health assessment platform in an outpatient setting to assess diagnostic accuracy.

The studies will focus on patients suffering from mild-Traumatic Brain Injury /Concussion and Alzheimer's disease, respectively.

On a combined basis, mTBI/Concussion and Alzheimer's disease affect over ten m Americans annually, and the inefficiencies of current behavior-based screening methodologies results in considerable excess cost and time to patients, clinicians and the healthcare system.

VoxNeuro's cognitive health software is expected to provide additive diagnostic information to improve clinical management beyond traditional testing methods. This represents a significant step forward for brain health as VoxNeuro provides for better identification and management strategies.

The studies will be led by Dr. John Connolly, PhD, VoxNeuro's chief science officer and Dr. Kyle Ruiter, PhD, VoxNeuro's vice president of Clinical and Scientific Affairs, alongside co-investigators Dr. Andrew Budson, MD, Professor of Neurology at Boston University School of Medicine and Associate director of Boston University's Alzheimer's Disease Research Center, and Dr. Katherine Turk, MD, Assistant Professor of Neurology at Boston University School of Medicine and co-Leader of the Outreach, Recruitment and Engagement Core at the Boston University Alzheimer's Disease Research Center.

VoxNeuro anticipates that this will continue to enhance its market awareness and will improve the ability of clinicians to accurately diagnose, treat, and aid in the management of patients suffering from mTBI/Concussion and Alzheimer's disease.

The company also anticipates that this work may support new regulatory filings with the FDA and Health Canada.

VoxNeuro is pushing the boundaries of brain health and empowering healthcare providers with a breakthrough SaMD technology that uses validated brain biomarkers.

The company's EEG-based reports deliver a comprehensive understanding of how a brain is functioning through the objective measurement of a patient's attention and concentration, information processing, and working memory.

VoxNeuro complements existing clinical workflow to provide clinicians and patients with a more complete picture of brain health, and to inform clinical decision-making.


Related Headlines